PPI Dosing After Angioectasia Source Control

Rationale for PPI Use

• The American Gastroenterological Association recommends using the lowest dose, frequency, and duration of PPIs in patients requiring PPI therapy 4
• PPIs are effective in reducing the risk of rebleeding in patients with high-risk bleeding stigmata in the upper GI tract 2

Recommended Outpatient PPI Regimen

• Initial outpatient therapy with standard once-daily dosing, such as omeprazole 20mg daily or pantoprazole 40mg daily, is recommended 1, 2
• The duration of therapy is recommended to be 4-8 weeks following angioectasia source control 1

Evidence Supporting Once-Daily Dosing

• The 2019 International Consensus Guidelines for Nonvariceal Upper GI Bleeding found no significant difference in rebleeding rates between high-dose and non-high-dose PPI regimens (OR 1.25, 95% CI 0.93 to 1.66) 2, 3

Special Considerations

• Patients with recurrent bleeding despite once-daily dosing, patients with multiple risk factors for rebleeding, and patients with advanced age (>60 years) may require special consideration 2, 5
• Concurrent anticoagulant or antiplatelet therapy is a risk factor for rebleeding 5, 6

Duration of Therapy and Deprescription

• After 4-8 weeks, reassess the need for continued PPI therapy and consider deprescription for patients without ongoing risk factors 1
• For patients with ongoing risk factors, consider maintenance therapy 5

Common Pitfalls to Avoid

• Overuse of twice-daily dosing is not supported by evidence for outpatient management after successful angioectasia source control 1
• Indefinite PPI therapy without reassessment carries potential risks, including C. difficile infection, community-acquired pneumonia, bone fracture risk, and micronutrient deficiencies 1, 4